Mölnlycke successfully prices a EUR 500M bond maturing 2034
Gothenburg, 4 June 2024: Mölnlycke, a world-leading MedTech company, has successfully raised EUR 500M in the corporate bond market under its Euro Medium Term Note (EMTN) programme. The bond has a 10-year tenor with an annual fixed coupon of 4.25%, corresponding to mid swaps of +1.55 percentage points.
The bond was more than five times oversubscribed with an orderbook of over EUR 2,700M at its peak. There was strong and widespread demand from leading investors in Germany, Austria and Switzerland 32%, UK & Ireland 28%, Nordics 18%, France 12% and Other 10%. Asset Managers represented 87% of investors, followed by Insurance and Pension Funds with 9% and Banks with 4%.
The proceeds will be used to finance a Tender Offer of Mölnlycke’s outstanding EUR 500M notes maturing in 2025 as well as for general corporate purposes. The bond further extends the duration of Mölnlycke’s well-spread debt maturity profile.
The bond will be listed on the Euro MTF market of the Luxembourg Stock Exchange.
BNP Paribas, ING, JP Morgan and SEB acted as joint bookrunners for the transaction.
Latest press releases
Go to Media room-
Mölnlycke Health Care annual report 2025 highlights sustainable growth and strategic transformation
Gothenburg, Sweden. 1 April 2026. Today, Mölnlycke Health Care has published its annual report 2025, including sustainability report, outlining the company’s continued focus on revolutionising care for people and planet.
-
Europe faces a growing chronic wound crisis – time to act is now
Gothenburg, Sweden. 31 March 2026. Mölnlycke®, a global leader in MedTech, today welcomes the publication of Shaping the future of wound care in Europe, the first joint industry white paper from the MedTech Europe Wound Care Sector Working Group. The wound paper highlights the growing burden of chronic wounds and urges EU policymakers to elevate wound care as a strategic health priority across the EU.
-
Mölnlycke Health Care AB: CEO, Zlatko Rihter, announces resignation, Guillaume Joucla appointed interim CEO
Tue, Mar 24, 2026 Today, it was announced that Zlatko Rihter, CEO of Mölnlycke Health Care, has informed the Board of Directors of his decision to resign. Following his decision, Guillaume Joucla, Chief Financial Officer, has been appointed interim CEO of Mölnlycke Health Care. Mölnlycke’s Board has initiated the recruitment process for a permanent CEO.
-
Mölnlycke joins National Climate Initiative within healthcare and life science
A broad public–private partnership is now being launched to accelerate the green transition within the Swedish healthcare and life science sector. The initiative aims, through collaboration, to reduce greenhouse gas emissions with the ambition of reaching net zero across the entire value chain by 2045.
-
Mölnlycke® celebrates 100 million ProcedurePak® trays - advancing operating room efficiency worldwide
Gothenburg, Sweden. 27 January 2026. Mölnlycke Health Care, a global leader in Medtech, headquarted in Gothenburg, Sweden, is celebrating the production of 100 million ProcedurePak® trays at the company's production sites in the Czech Republic.
-
Mölnlycke donates patent to spark innovation in sustainable healthcare
Gothenburg, Sweden. 12 November 2025. Mölnlycke Health Care, a global leader in MedTech, is the first company to donate a patent to SKF’s groundbreaking digital platform, The Patent Bay – taking bold action to harness collaboration and accelerate innovation in sustainable healthcare.
-
Mölnlycke establishes first wound care manufacturing site in China
Changshu, China, and Gothenburg, Sweden. 5 November 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke’s growth journey and the beginning of localised manufacturing in one of the world’s fastest-growing MedTech markets.
-
Mölnlycke Health Care’s global headquarters ranked number one workplace in Sweden and top 20 globally in Leesman workplace experience survey
Gothenburg, Sweden, 15 October 2025 Mölnlycke® Health Care is proud to announce that its global headquarters have placed number one in Sweden, and top 20 globally, in the prestigious Leesman® Index, a benchmark survey measuring workplace experience across thousands of organisations worldwide.
-
Mölnlycke Health Care breaks ground on $135 million expansion of Wound Care manufacturing facility in Brunswick, Maine
Brunswick, Maine, USA and Gothenburg, Sweden. 23 September 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, today celebrates the groundbreaking of a major expansion to its wound care manufacturing capacity in Brunswick, Maine. This milestone marks the beginning of a $135 million investment aimed at significantly increasing Mölnlycke’s manufacturing capacity in the United States.